Compare L3Harris Technologies Inc (LHX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Neurocrine Biosciences Inc — how do they compare? L3Harris Technologies Inc trades at $236.97 (market cap $44.12B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: L3Harris Technologies Inc is far larger — about 3.1× Neurocrine Biosciences Inc's market cap, and L3Harris Technologies Inc pays a 2.11% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LHX | NBIX | |
|---|---|---|
Market Cap | $44.12B | $14.36B |
Volume | 1,202,852 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $378.48 | $185.50 |
52-Week Low | $233.63 | $123.10 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $54.56B | $14.37B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $236.92, up 1.41% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains solid fundamentals with 7.34% net margin and $1.61B net income in 2025. Recent $6B THAAD contract win highlights defense sector strength, though multiple law firm investigations create investor uncertainty.
Outlook remains positive with analyst consensus target of $340 (44% upside), supported by defense budget tailwinds and projected 2026 revenue growth to $22.9B. Key risks include legal investigations and debt levels, but institutional buy ratings (73.5%) signal confidence in long-term defense contracting business model.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with technical indicators showing a bearish trend despite strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.85 significantly exceeding expectations of $1.85. Revenue growth remains strong, projected to increase from $2.9B in 2025 to $3.4B in 2026, while net profit margins expanded from 16.73% to 20.91%.
Wall Street maintains strong bullish sentiment with 86% buy ratings and a $204.18 consensus price target, representing 45% upside potential. Key risks include execution challenges with the expanding product portfolio and potential pricing pressure on INGREZZA ahead of 2029 patent considerations. The technical bearish signal contrasts with fundamental strength, creating potential entry opportunities for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
